Pioneering gene therapy patients stay on track, boosting Spark’s hemophilia B program
After rattling investors with early signs of an immune reaction in a couple of cases as well as an unexpected infusion for a suspected knee …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
